Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001576419-25-000573
Filing Date
2025-04-17
Accepted
2025-04-17 09:35:27
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5666
2 EXHIBIT 24: POWER OF ATTORNEY PowerOfAttorney.txt EX-24 2796
3 EXHIBIT 99: ITEM 7 Item_7.txt EX-99 721
  Complete submission text file 0001576419-25-000573.txt   11253
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-37761 | Film No.: 25844512
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock, Inc. (Filed by) CIK: 0002012383 (see all company filings)

EIN.: 991116001 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)